A detailed history of Aton Ra Partners transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 2,662 shares of ALNY stock, worth $651,897. This represents 1.02% of its overall portfolio holdings.

Number of Shares
2,662
Previous 2,935 9.3%
Holding current value
$651,897
Previous $519,000 1.93%
% of portfolio
1.02%
Previous 1.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$151.41 - $196.57 $41,334 - $53,663
-273 Reduced 9.3%
2,662 $509,000
Q3 2023

Oct 25, 2023

SELL
$170.77 - $211.65 $115,269 - $142,863
-675 Reduced 18.7%
2,935 $519,000
Q2 2023

Jul 18, 2023

SELL
$185.01 - $212.05 $29,231 - $33,503
-158 Reduced 4.19%
3,610 $685,000
Q1 2023

May 05, 2023

SELL
$182.66 - $235.53 $88,590 - $114,232
-485 Reduced 11.4%
3,768 $754,000
Q4 2022

Feb 02, 2023

SELL
$185.53 - $241.31 $329,501 - $428,566
-1,776 Reduced 29.46%
4,253 $1.01 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $5,957 - $9,976
-43 Reduced 0.71%
6,029 $1.21 Million
Q2 2022

Aug 15, 2022

SELL
$120.42 - $169.29 $422,553 - $594,038
-3,509 Reduced 36.62%
6,072 $886,000
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $18,949 - $25,912
149 Added 1.58%
9,581 $1.56 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $119,350 - $156,548
748 Added 8.61%
9,432 $1.6 Million
Q3 2021

Nov 15, 2021

BUY
$169.75 - $207.73 $99,643 - $121,937
587 Added 7.25%
8,684 $1.64 Million
Q2 2021

Aug 12, 2021

SELL
$128.63 - $176.89 $1.56 Million - $2.14 Million
-12,113 Reduced 59.94%
8,097 $1.37 Million
Q1 2021

May 17, 2021

BUY
$126.83 - $175.69 $1.63 Million - $2.25 Million
12,820 Added 173.48%
20,210 $2.85 Million
Q4 2020

Feb 19, 2021

BUY
$122.97 - $147.0 $908,748 - $1.09 Million
7,390 New
7,390 $960,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.